Repligen Co. (NASDAQ:RGEN) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA reduced its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 5.8% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 54,729 shares of the biotechnology company’s stock after selling 3,400 shares during the quarter. Primecap Management Co. CA’s holdings in Repligen were worth $6,899,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. Vanguard Group Inc. increased its holdings in shares of Repligen by 0.4% during the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after acquiring an additional 21,719 shares in the last quarter. Brown Capital Management LLC grew its position in Repligen by 5.8% during the 4th quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock worth $274,207,000 after purchasing an additional 83,416 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Repligen by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after purchasing an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC raised its holdings in shares of Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after buying an additional 199,322 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Repligen by 39.4% during the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after buying an additional 121,305 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Repligen

In other news, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by corporate insiders.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $142.03 on Thursday. The company has a market capitalization of $7.94 billion, a PE ratio of 568.12, a price-to-earnings-growth ratio of 4.20 and a beta of 0.94. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The company’s fifty day moving average price is $146.57 and its 200 day moving average price is $155.94. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. During the same period in the prior year, the company posted $0.53 EPS. The company’s revenue for the quarter was down 3.2% on a year-over-year basis. On average, research analysts predict that Repligen Co. will post 1.45 earnings per share for the current year.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and reduced their target price for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. Stephens restated an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. Wells Fargo & Company initiated coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price on the stock. JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. Finally, Benchmark reiterated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Repligen presently has an average rating of “Moderate Buy” and an average target price of $188.38.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.